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Abstract
Background: Participants in trials evaluating preventive interventions such as screening are on average healthier
than the general population. To decrease this ‘healthy volunteer effect’ (HVE) women were randomly invited from
population registers to participate in the United Kingdom Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS) and not allowed to self refer. This report assesses the extent of the HVE still prevalent in UKCTOCS and
considers how certain shortfalls in mortality and incidence can be related to differences in socioeconomic status.
Methods: Between 2001 and 2005, 202 638 postmenopausal women joined the trial out of 1 243 312 women
randomly invited from local health authority registers. The cohort was flagged for deaths and cancer registrations
and mean follow up at censoring was 5.55 years for mortality, and 2.58 years for cancer incidence. Overall and
cause-specific Standardised Mortality Ratios (SMRs) and Standardised Incidence Ratios (SIRs) were calculated based
on national mortality (2005) and cancer incidence (2006) statistics. The Index of Multiple Deprivation (IMD 2007)
was used to assess the link between socioeconomic status and mortality/cancer incidence, and differences
between the invited and recruited populations.
Results: The SMR for all trial participants was 37%. By subgroup, the SMRs were higher for: younger age groups,
extremes of BMI distribution and with each increasing year in trial. There was a clear trend between lower
socioeconomic status and increased mortality but less pronounced with incidence. While the invited population
had higher mean IMD scores (more deprived) than the national average, those who joined the trial were less
deprived.
Conclusions: Recruitment to screening trials through invitation from population registers does not prevent a
pronounced HVE on mortality. The impact on cancer incidence is much smaller. Similar shortfalls can be expected
in other screening RCTs and it maybe prudent to use the various mortality and incidence rates presented as
guides for calculating event rates and power in RCTs involving women.
Trial Registration: This study is registered as an International Standard Randomised Controlled Trial, number
ISRCTN22488978.
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In clinical studies, mortality and morbidity data from
the general population is used to calculate expected
death and incidence rates. However, volunteers partici-
pating in trials evaluating preventive interventions such
as screening are on average healthier than the general
population [1-3]. The implication of this ‘healthy volun-
teer effect (HVE)’ is that trial participants have lower
mortality and morbidity than the general population. In
randomised controlled trials (RCTs), this can cause a
shortfall in expected event rates which are the founda-
tion of the trial’s power calculations [4]. The latter
determine the sample size (number of participants
recruited and their time on the trial) and contribute sig-
nificantly to design, logistics and cost. A deficit could
mean a significant fall in power and may require altera-
t i o no ft h ed e s i g nm i d w a yt h r o u g ht h et r i a li ft h ep r i -
mary objective is to be achieved.
The United Kingdom Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS) is a large multi-centre
randomised controlled trial of 202 638 women recruited
between 2001 and 2005 [5]. In order to ensure trial
volunteers were as representative of the general popula-
tion as possible, women were not allowed to self refer.
Instead over 1.2 million women aged 50-74 were ran-
domly invited from age sex registers of 27 participating
local health authority registers [5]. The underlying
hypothesis was that the HVE is largely related to socioe-
conomic status with participants being more affluent,
better educated and more health-conscious than the
population as a whole. This bias was thought to be mag-
nified by recruitment using self-referral, which is depen-
dent on publicising the trial through a variety of media
such as newspapers, magazines, radio, television, posters
at numerous venues and meetings.
In this paper, we report on the impact of population
invitation on the HVE in UKCTOCS by comparing
observed and expected mortality and cancer incidence
rates in the trial, particularly with regard to socioeco-
nomic status levels. We also consider the differences in
deprivation of those invited with those recruited. The
results provide vital data to inform trial design and sam-
ple size calculations for those seeking to undertake
screening studies involving the general population.
Methods
Study Design
UKCTOCS is an RCT aiming to assess the impact of
screening on ovarian cancer mortality while comprehen-
sively evaluating performance characteristics, physical
and psychological morbidity, compliance, and cost of
the screening strategies. It was set up in 13 NHS Trusts
in England, Wales and Northern Ireland. Women living
in adjoining Primary Care Trusts (including Local
Health Boards in Wales) were invited to participate in
the trial. Those who accepted the invitation attended a
local recruitment clinic. Detailed description of the invi-
tation and recruitment process, as well as inclusion/
exclusion criteria, are detailed elsewhere [5]. Of rele-
vance to this analysis is that women with an active
malignancy were only eligible if they had no documen-
ted persistent or recurrent disease, and those with pre-
vious history of ovarian cancer were excluded. All
women provided written consent.
Follow up
Women recruited into the trial were ‘flagged’ for follow
up with the NHS Information Centre for Health and
Social Care (ICHSC) in England and Wales (for death
and cancer registration) and with the Central Services
Agency (CSA, for deaths in Northern Ireland) and
Cancer Registry in Northern Ireland (NICR). Almost all
women were successfully flagged (n = 202 593). From
the received death certificate copies, the ‘underlying
cause of death’ was used for the cause-specific observed
counts. Barring an inquest, death certificates were
mostly received within 3 months of the death. To
ensure completeness of data on deaths, events were cen-
sored on the 1
st June 2009, eight months prior to the
last death certificates update on 1
st February 2010. Data
provided by the CSA on cause of death was incomplete
and therefore women from Northern Ireland were
excluded from the calculation of cause-specific SMRs.
Information on all incident cancers can take up to
3 years to be recorded with the national registries. In
order to ensure completeness of data on cancers, events
were censored on 1
st June 2006, allowing a time lag of
3.75 years between events and the final cancer registration
update from NHS ICHSC and the NICR in February 2010.
Unlike the CSA, the NICR provided full data on cancer
type, so that all women were included in the cancer-
specific incidence analysis.
Analysis
Mortality and cancer incidence
Evidence of a HVE was assessed by calculation of the
Standardised Mortality Ratio (SMR) which is defined as
the ratio of observed to expected deaths (×100). A value
significantly less than 100 would indicate a HVE. SMRs
were calculated for: overall mortality (including ovarian
cancer); overall cancer (excluding ovarian cancer and
tubal cancer (ICD10-C56, C57.0) and ‘other malignant
neoplasms of skin’ (ICD10-C44); the 10 leading indivi-
dual causes of female cancer mortality (excluding ovar-
ian cancer); and the five leading general causes other
than cancer (circulatory, respiratory, digestive, nervous
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mortality, ovarian and fallopian tube cancers were
excluded from the analysis as they were the primary
outcome measure of the ongoing RCT.
The effect on cancer incidence from the HVE was
similarly assessed with the Standardised Incidence Ratio
(SIR), defined as the ratio of observed to expected
cancer incidence (×100). This was calculated again for
overall cancer (also excluding ICD10-C56, C57.0 and
C44) and the leading 10 female causes of cancer inci-
dence, excluding ovarian cancer. These are the same as
for mortality, although there are differences in the
rankings.
For each trial participant, Expected Mortality Rates
(EMRs) were calculated using national mortality rates
derived from ONS for 2005 [6]. All individual EMRs
were calculated for each year or partial year on the trial,
with the values summed over the number of years on
the trial. The individual’s risk of mortality was adjusted
for age at randomisation and also dynamically, so that
the risk reflected the ageing woman as the screening
progressed. The overall EMR for a cause was the sum of
each woman’s individual EMR up to the censoring date
of 1
st June 2009. ONS mortality tables for 2005 [6] pro-
vide both the number of female deaths for each cause as
well as total female population in 5 year age groups. To
estimate an age-specific mortality rate for each year,
firstly the midpoint of the age group was taken as repre-
senting the mortality rate calculated for that age group.
An approximate mortality rate estimate for any given
age was then calculated by imputing the age into either
a best fitting quadratic or exponential function. For
nearly all causes the fit was excellent with R
2 always
over 0.95 and mostly over 0.99. Similar analysis was per-
formed for cancer incidence using ONS cancer inci-
dence tables for 2006 [7]. The only exception was breast
cancer incidence where the effect of a national screening
programme meant that after the age of 70 the incidence
fell sharply, so that 2 separate functions had to be used
(below and above age 70). All confidence intervals for
the SMRs and SIRs were based on an assumed poisson
distribution for the observed deaths or cancers.
To calculate the EMR of each woman i (i = 1, 2...202
593) for cause of death z if:
￿ t is the year on trial (t = 1, 2...8)
￿ xi is the age of woman i at randomisation
￿ Dzx is the imputed mortality rate for cause of death
z at age x
￿ yti is the fraction of the year of trial t completed at
censoring or death by woman i (always = 1, except
for most recent/last year on trial)
then
EMR D y iz z x t ti
t
i = +−
=∑ [] (. )
, ...
05
12 8
and the overall EMR for cause of death z is simply:
EMR EMR zi z
i
=
= ∑
1 2 202593 , ...
Note that the age x imputed in Dzx is slightly adjusted
by 0.5 to approximate the average effect of ageing over
the year (t -0 . 5i n s t e a do ft-1). Also note, if women
withdraw from attending for screening in the trial at
any point, they continue to be followed up through flag-
ging for death and cancer registration. Hence no adjust-
ment is made for withdrawals.
Socioeconomic status
The PCT provided postcodes and dates of birth for all
women invited to the trial. The former was used to esti-
mate socio-economic class. The Index of Multiple
Deprivation 2007 (IMD) [8] provides 32 482 scores at a
Super Output Area (SOA) level linked to postcodes for
England. It was chosen over the other two census based
available indices (Townsend or Carstairs) as firstly, the
most up-to-date and secondly, the most precise in
ascribing a score to an individual based on postcode,
given that it is calculated at a much finer spatial scale.
Upon linking, an individual IMD score was derived for
156 620 women recruited in England. The women
recruited from centres in Wales and Northern Ireland
were omitted from this particular analysis. A Welsh
IMD (2008) [9] has been published. However, the differ-
ing criteria employed make comparisons between the
English and Welsh IMD scores invalid [10]. To explore
mortality versus deprivation, the recruited women were
separated into quintiles according to IMD score and the
respective SMRs compared. This was also repeated for
cancer incidence.
IMD scores for all women who were invited from
England were compared with those recruited to the trial
by evaluating their relative frequency distributions. No
mortality data is available for invited women.
Variation in HVE with age/region/BMI/time on trial
For all these analyses, the expected and observed mor-
tality rates for all relevant women in each group were
summed. Regional variations were compared by sum-
ming over the individual recruitment centres. For the
age group analysis the groupings were made by using
the age at randomisation to categorise into 50-54, 55-59,
60-65, 65-69 or 70-74 age groups. To assess any change
in the SMR/SIRs over the trial period, the overall EMR
was partitioned into year in trial by summing the indivi-
dual EMRs for each year t. This was done for the indivi-
dual causes of mortality and incidence, as well as for
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(BMI) of the women was explored by separating women
w h op r o v i d e dh e i g h ta n dw e i g ht at randomisation into
the standard underweight, normal, overweight and obese
categories (up to 18.5; 18.5-25; 25-30; over 30, respec-
tively) and comparing respective SMRs.
Results
1 243 282 women residing in 27 Primary Care Trusts
(including Local Health Boards in Wales) adjoining the
13 trial centres in England (10), Wales (2) and Northern
Ireland (1) were invited to participate in the trial.
Between 17th April 2001 and 29th September 2005, 202
638 women (157 973 England, 31 086 Wales, 13 579
Northern Ireland) were recruited and randomised [5].
Of those recruited from England and Wales, 35 were
unsuccessfully matched and 10 refused consent for flag-
ging, leaving 189 014 women from England and Wales
undergoing flagging through NHS ICHSC. All 13 579
women recruited from Northern Ireland were success-
fully matched by the Northern Ireland CSA. The aver-
age number of years on trial when mortality events were
censored on 1
st June 2009 for mortality was 5.55 years,
with over 99% having been on the trial for over 3 years,
and 24% over 7 years. Mean follow-up for incidence was
2.58 years at 1
st June 2006.
Mortality rates
There were only 4554 observed deaths compared to the
expected number of 12 247 based on 2005 national
mortality rates (Table 1). The SMR for overall mortality
was 37.3% (95% CI: 36.2, 38.4%). There was some varia-
tion of SMR across the 13 trial centres with the highest,
48.4% at Liverpool and the lowest, 30.9% at Bristol.
However across all centres there was a strong HVE with
less than half the expected deaths (Table 1).
For age group, there was an apparent decrease in the
SMRs as age increased, with the youngest group (50-54;
SMR = 47.3%) having a less pronounced HVE than the
other groups (Table 1). For BMI, both normal and over-
weight categories had similar SMRs of around 34%
whereas the extreme categories had higher mortality
rates, particularly the underweight category (70.6%)
The overall cancer SMR was 55.9%. There was some
variation between the different cancer types but all were
between 42.9% (breast) and 79.8% (pancreatic), with
mortality significantly lower than expected (100%). The
HVE was even stronger for the other major causes of
mortality (Table 2).
There was a clear increase in the SMRs as time in trial
increased (Table 3). The overall SMR was low in the 1
st
year (18.5%) but rose steadily to 49.0% by the 8
th year.
With the exception of stomach cancer all of the cause-
specific 1
st year SMRs for mortality were significantly
below 100% with some particularly low values such as
5.3% for breast cancer (Table 3). These figures showed
an increasing trend as the study progressed, though not
nearly as consistently as for overall mortality, and given
the lower numbers, with wider confidence intervals. Of
the cancers only lung, breast and colorectal had 6 or
more study years where the confidence interval for the
SMR did not contain 100.
Socioeconomic status comparison
Based on IMD score quintiles, there was a general trend
between deprivation and mortality with higher SMRs for
increasing levels of deprivation (Table 4). Specifically,
the lowest (least deprived) two quintiles had a similar
SMR of around 30% with the most deprived having a
SMR of 52.3%. The rising trend between overall cancer
incidence and increasing deprivation was less obvious.
Figure 1 shows the relative frequency distributions for
IMD score. Although the distributions show similarity
in trend and location, the more peaked distribution of
those who joined, and the crossover of distributions at
an IMD score of 20, imply that the trial participants
were less deprived than the invited population.
Cancer Incidence
The situation regarding cancer incidence (Table 5) was
rather different. For overall cancer the SIR was 88.1%,
higher than the 55.9% for overall cancer mortality. Of
the individual cancers, only for lung, pancreatic, oeso-
phageal and colorectal cancers did the confidence inter-
val for the SIR not contain 100, and only for pancreatic
and oesophageal cancer was the SMR higher than the
SIR.
Regarding incidence over time (Table 6), there were
far fewer occasions compared to mortality where the
whole confidence interval for the SIR was below 100,
with only lung cancer having a consistently low SIR
over time (between 27.1% and 65.9%). Apart from lung
cancer and leukaemia, the cancer specific SIRs were not
particularly low in the first year compared to the com-
plete study period. For overall cancer the SIRs were
remarkably consistent over time, between 84.6% and
91.7%.
Discussion
This is the first report to explore the impact of a
‘healthy volunteer effect’ from inviting potential partici-
pants randomly from population registers as opposed to
self-referral. The overall SMR compared to the 2005
population of England and Wales was 37.3%. The figure
is almost identical to the overall SMR of 38% reported
for women in the US PLCO screening trial [2] where
participants were allowed to self refer or invited through
mass mailings using motor-vehicle registrations and
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population based [11]. This introduces additional bias,
as the types of advertising media (radio station, website,
newspaper or magazine) or mailing lists used, limit
those who have access to the information. In contrast,
in UKCTOCS over 1.2 million women (1 in 6 of the UK
population in the eligible age range) were randomly
invited from health authority registers. It was anticipated
that such invitation would result in participants being
more representative of the general population than
those recruited through advertisement and self referral.
However, even with this safeguard there continued to be
a pronounced HVE on mortality, both overall and
cause-specific. The data highlights again the selection
bias that occurs in clinical trials and emphasises the
need for randomised controlled trials rather than obser-
vational studies to determine efficacy of screening and
prevention strategies. There was a much lesser effect on
cancer incidence relative to the general population.
The magnitude of the HVE in a trial is dependent on a
variety of other factors in addition to mode of recruitment.
Eligibility criteria can play a crucial role. This includes
gender, where in the PLCO trial the HVE was less pro-
nounced in men, who had a statistically significantly
higher SMR than women for all-cause mortality (46% ver-
sus 38%), all cancer mortality, respiratory diseases, dia-
betes, cardiovascular diseases, and non-Hodgkin’s
lymphoma [2]. Most screening/prevention trials exclude
Table 1 Standardized Mortality Ratios (SMR) for overall mortality and by subgroup
Number Expected Mortality Observed Mortality SMR L95%CI U95%CI
OVERALL 202593 12247 4569 37.3% 36.2% 38.4%
CENTRE
Gateshead 17321 1140 469 41.1% 37.5% 45.0%
St Barts London 19963 1199 474 39.5% 36.0% 43.2%
Liverpool 10108 613 297 48.4% 43.1% 54.3%
Nottingham 16765 1091 430 39.4% 35.8% 43.3%
Manchester 16498 940 375 39.9% 35.9% 44.1%
Derby 14917 858 312 36.4% 32.5% 40.7%
Royal Free London 16709 920 306 33.3% 29.7% 37.2%
Portsmouth 19175 1341 490 36.5% 33.4% 39.9%
Bristol 16556 1108 342 30.9% 27.7% 34.3%
Belfast 13579 750 241 32.2% 28.2% 36.5%
Cardiff 16756 886 338 38.2% 34.2% 42.5%
North Wales 14324 861 298 34.6% 30.8% 38.8%
Middleborough 9922 541 197 36.4% 31.5% 41.9%
AGE GROUP
50-54 39392 882 417 47.3% 42.8% 52.0%
55-59 55592 1977 825 41.7% 38.9% 44.7%
60-64 47073 2658 948 35.7% 33.4% 38.0%
65-69 38568 3530 1259 35.7% 33.7% 37.7%
70-74 21967 3200 1120 35.0% 33.0% 37.1%
BMI SCORE
Underweight (up to 18.5) 2548 157 111 70.6% 58.1% 85.0%
Normal (18.5-25) 82888 4903 1701 34.7% 33.1% 36.4%
Overweight (25-30) 74284 4640 1586 34.2% 32.5% 35.9%
Obese (over 30) 41903 2486 1113 44.8% 42.2% 47.5%
YEAR IN TRIAL (women years)
1
st 202501 1732 320 18.5% 16.5% 20.6%
2
nd 202028 1914 660 34.5% 31.9% 37.2%
3
rd 201314 2111 800 37.9% 35.3% 40.6%
4
th 197029 2290 903 39.4% 36.9% 42.1%
5
th 156319 1955 841 43.0% 40.2% 46.0%
6
th 106119 1393 631 45.3% 41.8% 49.0%
7
th 49590 719 349 48.6% 43.6% 53.9%
8
th 8136 133 65 49.0% 37.9% 62.5%
Average time on trial = 5.55 yrs/woman.
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bly affect the cancer specific SMRs in the early years.
There was a clear upward trend in the cancer specific
SMRs, despite widening confidence intervals, when exam-
ined by ‘year in trial’. In the first year, most were below
25%. It is feasible that the other exclusion criteria may also
have had health implications. Women who had undergone
bilateral oophorectomy were ineligible. Recent reports
have shown increased mortality in women in this sub-
group who do not use oestrogen replacement until the age
of 45 [12,13]. Finally, higher participations rates may be
expected to reduce the self-selection effect. In UKCTOCS
Table 2 Standardized Mortality Ratios (SMRs) for overall cancer, the 10 leading causes of cancer mortality and 5 other
causes of mortality
MORTALITY CAUSE ICD-10 Code Expected mortality Observed Mortality SMR L95%CI U95%CI
Cancers Overall C00:C99 excl. C56, C57.0, C44 4419 2469 55.9% 53.7% 58.1%
Lung Cancer C33:C34 1020 499 48.9% 44.7% 53.4%
Breast Cancer C50 813 349 42.9% 38.6% 47.7%
Colorectal Cancer C18:C21 415 218 52.6% 45.8% 60.1%
Pancreatic Cancer C25 244 195 79.8% 69.0% 91.8%
Oesophagus Cancer C15 111 85 76.4% 61.0% 94.5%
Stomach Cancer C16 85 64 75.1% 57.8% 95.9%
N-H Lymphoma C82:C85, C96 194 88 45.4% 36.4% 55.9%
Leukaemia C91:C95 107 49 45.9% 33.9% 60.6%
Uterus Cancer C54:C55 120 63 52.3% 40.2% 66.9%
Bladder Cancer C67 68 32 46.7% 32.0% 66.0%
Mental Behaviours Deaths F- 127 9 7.1% 3.2% 13.4%
Nervous System Deaths G- 344 92 26.8% 21.6% 32.8%
Circulatory Deaths I- 3208 999 31.1% 29.2% 33.1%
Respiratory Deaths J- 1179 261 22.1% 19.5% 25.0%
Digestive Deaths K- 688 187 27.2% 23.4% 31.4%
Ovarian (C56)/tubal cancer (C57.0) and other malignant neoplasm of skin (C44) have been excluded. Average time on trial at censoring (1
st June 2009) = 5.55 yrs/
woman.
Table 3 Standardized Mortality Ratios for various causes by year in trial
Year of Study Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Overall
Women years 188926 188467 187776 183826 146094 99763 46820 8057 1049731
Overall 18.5% 34.5% 37.9% 39.4% 43.0% 45.3% 48.6% 49.0% 37.3%
Cancers Overall 19.7% 49.7% 61.3% 59.9% 70.4% 74.7% 64.8% 55.8% 55.9%
Lung Cancer 23.7% 37.7% 62.4% 51.9% 63.9% 48.3% 61.9% 18.9% 48.9%
Breast Cancer 5.3% 39.2% 37.6% 48.4% 67.4% 72.8% 43.8% 40.4% 42.9%
Colorectal Cancer 18.4% 57.9% 59.9% 54.4% 59.8% 75.5% 33.6% 44.1% 52.6%
Pancreatic Cancer 27.5% 78.5% 98.3% 57.4% 89.6% 138.2% 96.6% 83.4% 79.8%
Oesophagus Cancer 14.7% 64.0% 84.2% 91.1% 85.2% 151.7% 108.2% 124.1% 76.4%
Stomach Cancer 62.9% 117.8% 68.9% 73.9% 85.4% 19.8% 93.3% 94.6% 75.1%
N-H Lymphoma 10.5% 35.3% 41.4% 44.6% 53.2% 70.4% 111.3% 49.5% 45.4%
Leukaemia 6.4% 46.8% 43.0% 30.2% 48.0% 109.8% 49.9% 176.6% 45.9%
Uterus Cancer 11.0% 66.2% 42.6% 67.5% 75.7% 68.8% 0.0% 83.1% 52.3%
Bladder Cancer 10.9% 19.3% 60.1% 61.7% 53.6% 49.8% 70.5% 118.6% 46.7%
Mental Behaviours Deaths 6.7% 0.0% 4.8% 4.1% 4.5% 6.2% 22.4% 107.0% 7.1%
Nervous System Deaths 6.1% 22.2% 20.2% 31.2% 27.5% 43.8% 59.9% 25.9% 26.8%
Circulatory Deaths 25.7% 31.7% 31.0% 31.9% 32.8% 26.7% 41.2% 38.6% 31.1%
Respiratory Deaths 9.1% 16.6% 18.6% 23.7% 25.1% 29.7% 35.7% 65.9% 22.1%
Digestive Deaths 15.7% 29.9% 22.6% 27.5% 24.3% 36.9% 41.5% 82.2% 27.2%
Ovarian (C56)/tubal cancer (C57.0) and other malignant neoplasm of skin (C44) have been excluded. Average time on trial at censoring (1
st June 2009) = 5.55 yrs/
woman. Note the number of ‘Women years’ relates to individual causes and not to overall mortality due to exclusion of Northern Ireland women. Italicised values
have 95% confidence intervals not containing 100.
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ticipate in the trial but finally only 16% were randomised
[5].
The overall 1
st year SMR was 18.5%, rising to 35% in
the 2
nd year and nearly 50% by the 8
th year. The SMRs
have been age-adjusted dynamically so this is not a
result of the age-related increase in risk. Similar trends
were seen in the PLCO trial. In both studies by the 7
th
year the SMR was 48%. A major contributing factor to
the SMR trend with time is the health-screening nature
of volunteering. The huge shortfall in SMRs for the first
year of UKCTOCS, particularly causes other than can-
cer, are strong indicators that women suffering from
poor health or chronic non-cancer illness tend not to
volunteer [4]. Their health concerns naturally lie with
their immediate real problems rather than a future
potential issue. Some of these conditions may well pre-
dispose to earlier mortality. It is interesting that the
younger age groups, specifically 50-54, had higher
SMRs. This suggests that women in the younger groups
may more closely represent their national counterparts.
We were unable to find in the literature reports where
differences in (age-adjusted) SMRs were explored by
age, but if confirmed, one possible explanation is that
there may be less prevalent morbidity that might hinder
volunteering at these ages. Mental and behavioural
deaths had the lowest SMRs and the need for informed
consent could have been a contributory factor. For gen-
eral health, the commonly reported u-shaped curve
[14-16] relating BMI to mortality was seen, with the
highest SMRs belonging to those underweight and obese
(Table 1).
The HVE is often ascribed to the fact that educated
women who are financially better off and have a healthier
lifestyle are more likely to volunteer for a screening trial,
where health awareness and the means to travel to the
trial centre influence a women’s decision. While difficult
to substantiate directly, many of these factors are linked
to indices of social deprivation and in UKCTOCS the
availability of postcodes for all invited women made it
possible to calculate deprivation (IMD) scores for all invi-
tees from England. Figure 1 shows that the cohort of
invited women was more deprived (higher IMD scores:
mean = 24.7) than those who subsequently joined the
trial (mean score = 19.6). The reported mean IMD score
for England is 21.6 [17]. Our invited population was
more deprived than the national average probably as a
result of a higher proportion of urban centres. However,
as has been shown, those who actually volunteered were
Table 4 Standardized Mortality Ratios (SMR) and Standardized Incidence Ratios (SIR) by deprivation (IMD) quintile
Mortality by deprivation Number Expected Mortality Observed Mortality SMR L95%CI U95%CI
IMD SCORE (deprivation index)
1st quintile (up to 7.8) 31231 1985 604 30.4% 28.0% 33.0%
2nd quintile (7.8-12.3) 31203 1912 591 30.9% 28.5% 33.5%
3rd quintile (12.3-18.5) 31254 1884 721 38.3% 35.5% 41.2%
4th quintile (18.5-30.2) 31326 1901 707 37.2% 34.5% 40.0%
5th quintile (over 30.2) 31263 1959 1024 52.3% 49.1% 55.6%
Cancer incidence by deprivation Number Expected Incidence Observed Incidence SIR L95%CI U95%CI
IMD SCORE (deprivation index)
1st quintile (up to 7.8) 31231 736 593 80.6% 74.2% 87.4%
2nd quintile (7.8-12.3) 31203 715 590 82.6% 76.0% 89.5%
3rd quintile (12.3-18.5) 31254 705 601 85.2% 78.5% 92.3%
4th quintile (18.5-30.2) 31326 725 589 81.3% 74.9% 88.1%
5th quintile (over 30.2) 31263 786 715 91.0% 84.4% 97.9%
Average time on trial = 5.55 yrs/woman for SMRs and = 2.58 yrs/woman for SIRs.
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Figure 1 Relative frequency distributions of IMD score for
those invited to UKCTOCS and those that joined UKCTOCS
(English postcodes only).
Burnell et al. Trials 2011, 12:61
http://www.trialsjournal.com/content/12/1/61
Page 7 of 10less deprived. Of note, Bristol and Portsmouth, which
were the least deprived (lowest mean IMD) among the 10
English centres, had the highest acceptance rates of invi-
tations among all 13 centres [5]. This suggests that postal
invitation alone will not persuade women from deprived
backgrounds to participate.
Socioeconomic status is known to be linked to most
causes of mortality, including cancers. Bristol, which
had the 2
nd lowest mean IMD score had the lowest
SMR, while Liverpool, with the highest mean IMD
score, had the highest SMR (48.4%). Further support is
provided by the trend of higher SMRs with increasing
levels of deprivation across the 5 quintiles, from the
least deprived (SMR = 30.4%) to the most deprived
(SMR = 52.3%) (Table 5).
The most striking aspect on comparing cause-specific
incidence and mortality rates was that the SIRs were
higher than the SMRs and, for the leading cancers other
than lung, pancreas, oesophagus and colorectal (just),
the SIR confidence intervals crossed 100. In a recent
analysis of US data, while late-stage diagnoses in all
cancers (with resultant higher mortality) were associated
with lower socioeconomic status, incidence of only cer-
tain specific cancers varied with socioeconomic status
[18]. Pollock et al noted that while mortality increased
with deprivation among patients suffering from lung,
breast and colorectal cancers in the South Thames area,
for incidence this was only observed in lung cancer [19].
Official national statistics for England and Wales show a
mixture of positive (notably lung and cervix), negative
(breast, leukaemia) and zero association (colorectal)
between different cancer type incidences and deprivation
[20]. The three cancers (lung, oesophagus and pancreas)
with the largest shortfalls in SIRs in UKCTOCS have a
strong link to smoking [21-23]. Individuals with lower
socio-economic status are more likely to be current
smokers, physically inactive and obese [24]. In all three
of these cancers, there are reports of negative correla-
tion between incidence and socioeconomic status
[18-20,25,26]. Conversely, in breast cancer the SIR was
Table 5 Standardized Incidence Ratios (SIRs) for overall cancer and the 10 leading causes of cancer
INCIDENCE ICD-10 Code Expected incidence Observed Incidence SIR L95%CI U95%CI
Cancers Overall C00:C99 excl. C56, C57.0, C44 4610 4131 88.1% 85.4% 90.9%
Lung Cancer C33:C34 582 328 56.2% 50.2% 62.6%
Breast Cancer C50 1715 1748 99.8% 95.1% 104.6%
Colorectal Cancer C18:C21 511 471 91.1% 83.1% 99.8%
Pancreatic Cancer C25 122 84 68.1% 54.3% 84.4%
Oesophagus Cancer C15 75 54 71.6% 53.8% 93.4%
Stomach Cancer C16 65 56 85.0% 64.0% 110.6%
N-H Lymphoma C82:C85, C96 168 175 103.6% 88.8% 120.2%
Leukaemia C91:C95 75 58 77.7% 59.0% 100.4%
Uterus Cancer C54:C55 318 293 91.1% 80.9% 102.2%
Bladder Cancer C67 77 64 79.5% 60.8% 102.1%
Ovarian (C56)/tubal cancer (C57.0) and other malignant neoplasm of skin (C44) have been excluded. Average time in trial at censoring (1
st June 2006) = 2.58 yrs/
woman.
Table 6 Standardized Incidence Ratios for 10 leading causes of cancer by year in trial
Year of Study Year 1 Year 2 Year 3 Year 4 Year 5 Overall
Women years 198967 158235 107587 50362 8296 523447
Cancers Overall (excl. C56, C57.0, C44) 84.6% 90.8% 88.5% 91.7% 91.4% 88.1%
Lung Cancer 45.0% 61.5% 65.9% 64.1% 27.1% 56.2%
Breast Cancer 100.0% 106.1% 90.5% 99.9% 95.3% 99.8%
Colorectal Cancer 87.2% 96.7% 84.5% 98.4% 112.0% 91.1%
Pancreatic Cancer 57.4% 65.4% 88.4% 83.5% 0.0% 68.1%
Oesophagus Cancer 73.8% 61.6% 99.8% 37.1% 68.8% 71.6%
Stomach Cancer 78.5% 102.6% 72.2% 70.2% 152.7% 85.0%
N-H Lymphoma 91.5% 92.7% 137.8% 102.7% 131.1% 103.6%
Leukaemia 44.6% 75.5% 101.0% 138.1% 140.0% 77.7%
Uterus Cancer 96.3% 92.7% 94.1% 58.7% 109.2% 91.1%
Bladder Cancer 59.0% 90.9% 103.2% 82.6% 0.0% 79.5%
Ovarian (C56)/tubal cancer (C57.0) and other malignant neoplasm of skin (C44) have been excluded. Average time in trial at censoring (1
st June 2006) = 2.58 yrs/
woman. Italicised values have 95% confidence intervals not containing 100.
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Page 8 of 10102% whilst the SMR was 43%, in keeping with pre-
viously reported associations between higher socioeco-
nomic status and higher incidence of localised breast
cancer but lower regional breast cancer mortality
[25,27]. Women who volunteer for a screening trial are
more likely to attend for breast screening and to be
diagnosed with early stage disease. Overdiagnosis of
breast cancer in the screened population could also con-
tribute to higher incidence but lower mortality [28].
Despite the strong similarity of results for overall mor-
tality between UKCTOCS and the PLCO trial there is
less commonality when cause-specific results are com-
pared. While pancreatic cancer has the highest SMR in
both studies, large discrepancies exist for cancers such as
uterus (52% UKCTOCS versus 22% PLCO), stomach
(75% versus 41%) and oesophagus (76% versus 41%).
Given the smaller numbers in these subgroups, some of
these differences may be purely random. Most of these
cancers are also associated with lower SIRs in the PLCO
trial compared to UKCTOCS: oesophageal (72% UKC-
TOCS versus 38% PLCO), stomach cancer (85% versus
48%) and bladder (80% versus 52%). It needs to be noted
that there are subtle differences in the PLCO entry cri-
teria when compared to UKCTOCS, such as minimum
age (55 versus 50 in UKCTOCS) and inclusion of women
who had undergone bilateral oophorectomy.
T h em o s tr e c e n t l yp u b l i s h e ds tatistics for mortality
(for 2005, published 2006 [6]) and incidence (for 2006,
published 2008 [7]) produced by ONS were used to cal-
culate EMRs for the period 2001-2009 so the data can
be considered broadly representative. An additional
issue is that the ‘national’ mortality rates were based on
data from England and Wales only but was used to cal-
culate EMRs for the 13 579 women from Northern Ire-
land. There were also approximations involved in the
actual calculations, such as the age-group mortality rates
representing the midpoint of that group and specific
age-adjusted rates estimated by use of a best-fitting sim-
ple model. The EMRs were also assumed to be fixed
values when calculating the confidence intervals. They
are estimates, as they are based on national data that
varies yearly through a random component, in addition
to any real change. However comparison of ONS’s2 0 0 4
and 2005 (logged) mortality rates showed a high level of
linear correlation, with all Pearson correlations for the
major cancer causes over 0.99, except those for uterus
(r = 0.984) and non-Hodgkin’s lymphoma (r =0 . 9 8 1 ) .
This suggests any yearly changes in mortality rates (real
shifts or random fluctuations) are small and treating
them as fixed was not unreasonable.
Conclusions
The lack of mortality or incidence events can severely
harm a clinical trial’s ability to demonstrate efficacy.
Other ramifications of the HVE inevitably include con-
cerns over external validity of a demonstrated screening
benefit, though that would imply some level of interac-
tion between screening and volunteer characteristics. It
may be hard to perceive how social factors could influ-
ence screening success directly at the point of interven-
tion, though certainly compliance with a screening
programme can be dependent upon the level of social
deprivation [29]. Either way, one may regard this as a
realistic aspect of a national screening programme. In
UKCTOCS, the HVE has necessitated revision of the
trial design in 2008, with extension of screening in the
study arm until 31
st Dec 2011 and follow up until 31
st
Dec 2014 [30]. During planning of this trial in 1999, no
published data was available to estimate the impact of
the HVE. The various mortality rates presented here are
based on over one million study years, and incidence
rates on over half a million study years. They provide
vital information for investigators on likely event rate
shortfalls that might be expected in ongoing and future
screening studies/RCTs of similar design.
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